Structure Therapeutics (GPCR) vs Lakefront Biotherapeutics (LKFT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Lakefront Biotherapeutics (LKFT) has outperformed Structure Therapeutics (GPCR) over the past year, losing 12.6% versus a loss of 16.4%. Lakefront Biotherapeutics is the larger company by market cap ($1.95 billion vs $1.82 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | LKFT |
|---|---|---|
| Share price | $25.54 | $29.73 |
| Market cap | $1.82B | $1.95B |
| 1-day change | -0.51% | +0.75% |
| YTD return | -63.28% | -9.08% |
| 1-year return | -16.40% | -12.61% |
| 5-year return | — | -44.45% |
| P/E ratio (TTM) | — | 2.83 |
| EPS (TTM) | $-3.03 | $10.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-141.20M | — |
| 52-week high | $94.90 | $36.24 |
| 52-week low | $25.09 | $25.68 |
| Distance from 52-week high | -73.09% | -17.96% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +314.17% | +1.51% |
| Average volume | 968.62K | 275.47K |
| Shares outstanding | 71.31M | 65.48M |
| Employees | 281 | 196 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
GPCR vs LKFT FAQ
Which is bigger, Structure Therapeutics or Lakefront Biotherapeutics?
Lakefront Biotherapeutics (LKFT) is larger, with a market capitalization of $1.95B compared with $1.82B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, GPCR or LKFT?
LKFT returned -12.61% over the past 12 months, compared with -16.40% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Lakefront Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.